Dimethyl Myleran Therapy Combined with Abdominal Aortic Occlusion
1964

Dimethyl Myleran Therapy for Cancer

Sample size: 15 publication Evidence: moderate

Author Information

Author(s): Peter Clifford, R. A. Clift, A. G. Khan, G. M. Timmis

Primary Institution: King George VI Hospital, Nairobi, Kenya and the Chester Beatty Research Institute, Institute of Cancer Research: Royal Cancer Hospital, London

Hypothesis

Can dimethyl Myleran combined with abdominal aortic occlusion effectively treat advanced malignant diseases of the head and neck?

Conclusion

Dimethyl Myleran therapy resulted in marked tumor regression in some patients, but also caused significant toxicity.

Supporting Evidence

  • Eight out of the fifteen cases treated had marked tumour regression.
  • One patient was discharged histologically free of disease.
  • Dimethyl Myleran was found to be free from neurological toxicity.
  • Common complications included bucco-labial mucositis, alopecia, and thrombocytopenia.

Takeaway

Doctors tried a new cancer treatment called dimethyl Myleran, and it helped some patients feel better, but it also made them very sick.

Methodology

Patients received dimethyl Myleran intravenously after abdominal aortic occlusion, with varying doses and occlusion times.

Limitations

The study had a small sample size and significant toxicity was observed.

Participant Demographics

Patients had advanced malignant diseases, including anaplastic carcinoma and plasmacytoma.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication